GB2575623B - 3-hydroxybutyrate esters for treating cancer cachexia - Google Patents

3-hydroxybutyrate esters for treating cancer cachexia Download PDF

Info

Publication number
GB2575623B
GB2575623B GB1809113.2A GB201809113A GB2575623B GB 2575623 B GB2575623 B GB 2575623B GB 201809113 A GB201809113 A GB 201809113A GB 2575623 B GB2575623 B GB 2575623B
Authority
GB
United Kingdom
Prior art keywords
treating cancer
cancer cachexia
hydroxybutyrate esters
hydroxybutyrate
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1809113.2A
Other languages
English (en)
Other versions
GB201809113D0 (en
GB2575623A (en
Inventor
Clarke Kieran
Hespel Peter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tdeltas Ltd
Original Assignee
Tdeltas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tdeltas Ltd filed Critical Tdeltas Ltd
Priority to GB1809113.2A priority Critical patent/GB2575623B/en
Publication of GB201809113D0 publication Critical patent/GB201809113D0/en
Priority to ES19730484T priority patent/ES3014285T3/es
Priority to PL19730484.3T priority patent/PL3801490T3/pl
Priority to KR1020217000016A priority patent/KR102863322B1/ko
Priority to EP19730484.3A priority patent/EP3801490B1/en
Priority to US15/734,159 priority patent/US12226387B2/en
Priority to CN201980038028.5A priority patent/CN112384211B/zh
Priority to PCT/GB2019/051532 priority patent/WO2019234402A1/en
Priority to CA3102503A priority patent/CA3102503A1/en
Priority to JP2020567530A priority patent/JP7402826B2/ja
Priority to DK19730484.3T priority patent/DK3801490T3/da
Publication of GB2575623A publication Critical patent/GB2575623A/en
Application granted granted Critical
Publication of GB2575623B publication Critical patent/GB2575623B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
GB1809113.2A 2018-06-04 2018-06-04 3-hydroxybutyrate esters for treating cancer cachexia Active GB2575623B (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GB1809113.2A GB2575623B (en) 2018-06-04 2018-06-04 3-hydroxybutyrate esters for treating cancer cachexia
CN201980038028.5A CN112384211B (zh) 2018-06-04 2019-06-03 用于癌症恶病质的化合物
CA3102503A CA3102503A1 (en) 2018-06-04 2019-06-03 Compounds for use in cancer cachexia
KR1020217000016A KR102863322B1 (ko) 2018-06-04 2019-06-03 암 악액질에 사용하기 위한 화합물
EP19730484.3A EP3801490B1 (en) 2018-06-04 2019-06-03 Compounds for use in cancer cachexia
US15/734,159 US12226387B2 (en) 2018-06-04 2019-06-03 Compounds for use in cancer cachexia
ES19730484T ES3014285T3 (en) 2018-06-04 2019-06-03 Compounds for use in cancer cachexia
PCT/GB2019/051532 WO2019234402A1 (en) 2018-06-04 2019-06-03 Compounds for use in cancer cachexia
PL19730484.3T PL3801490T3 (pl) 2018-06-04 2019-06-03 Związki do zastosowania w kacheksji nowotworowej
JP2020567530A JP7402826B2 (ja) 2018-06-04 2019-06-03 がん悪液質において用いる化合物
DK19730484.3T DK3801490T3 (da) 2018-06-04 2019-06-03 Forbindelser til anvendelse i cancerkakeksi

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1809113.2A GB2575623B (en) 2018-06-04 2018-06-04 3-hydroxybutyrate esters for treating cancer cachexia

Publications (3)

Publication Number Publication Date
GB201809113D0 GB201809113D0 (en) 2018-07-18
GB2575623A GB2575623A (en) 2020-01-22
GB2575623B true GB2575623B (en) 2022-10-26

Family

ID=62872859

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1809113.2A Active GB2575623B (en) 2018-06-04 2018-06-04 3-hydroxybutyrate esters for treating cancer cachexia

Country Status (11)

Country Link
US (1) US12226387B2 (https=)
EP (1) EP3801490B1 (https=)
JP (1) JP7402826B2 (https=)
KR (1) KR102863322B1 (https=)
CN (1) CN112384211B (https=)
CA (1) CA3102503A1 (https=)
DK (1) DK3801490T3 (https=)
ES (1) ES3014285T3 (https=)
GB (1) GB2575623B (https=)
PL (1) PL3801490T3 (https=)
WO (1) WO2019234402A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12396974B2 (en) 2020-03-27 2025-08-26 KetoneAid Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
CN118591523A (zh) * 2021-11-12 2024-09-03 阿萨达股份公司 多元醇衍生的化合物
KR20250145172A (ko) 2024-03-28 2025-10-13 한림대학교 산학협력단 암 악액질의 예방 또는 치료를 위한 약학 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108740A2 (en) * 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
WO2010021766A1 (en) * 2008-08-21 2010-02-25 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
WO2013150153A1 (en) * 2012-04-05 2013-10-10 Tdeltas Limited Ketone bodies and ketone body esters for maintaining or improving muscle power output
GB2517088A (en) * 2013-08-07 2015-02-11 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
WO2018114309A1 (en) * 2016-12-23 2018-06-28 Katholieke Universiteit Leuven 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3104396B1 (en) 2003-06-13 2018-03-21 Nikon Corporation Exposure method, substrate stage, exposure apparatus, and device manufacturing method
US8642654B2 (en) * 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
JP5269128B2 (ja) 2010-03-12 2013-08-21 エーエスエムエル ネザーランズ ビー．ブイ． リソグラフィ装置および方法
WO2014085652A1 (en) 2012-11-28 2014-06-05 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108740A2 (en) * 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
WO2010021766A1 (en) * 2008-08-21 2010-02-25 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
WO2013150153A1 (en) * 2012-04-05 2013-10-10 Tdeltas Limited Ketone bodies and ketone body esters for maintaining or improving muscle power output
GB2517088A (en) * 2013-08-07 2015-02-11 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
WO2018114309A1 (en) * 2016-12-23 2018-06-28 Katholieke Universiteit Leuven 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
American Journal of Clinical Nutrition, vol. 47, No. 1, 1988, pages 42-48 *
British Journal of Cancer, vol. 56, 1987, pages 39-43 *
British Journal of Cancer, vol. 58, 1988, pages 580-583 *
Cancer & Metabolism, vol. 2, 2014, pages 1-19 *
International Journal of Pancreatology, vol. 7, No. 1-3, 1990, pages 141-150 *
Nutrients, vol. 10, No. 206, 2018, Nakamura et al. "A ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice", pages 1-10 [Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852782/] *
The Australian Journal of Experimental Biology and Medical Science, vol. 57, No. 5, 1979, pages 529-539 *

Also Published As

Publication number Publication date
PL3801490T3 (pl) 2025-04-14
EP3801490B1 (en) 2024-12-04
CA3102503A1 (en) 2019-12-12
JP7402826B2 (ja) 2023-12-21
GB201809113D0 (en) 2018-07-18
US12226387B2 (en) 2025-02-18
CN112384211A (zh) 2021-02-19
JP2021525775A (ja) 2021-09-27
DK3801490T3 (da) 2025-03-03
CN112384211B (zh) 2025-01-03
US20210212977A1 (en) 2021-07-15
ES3014285T3 (en) 2025-04-21
EP3801490A1 (en) 2021-04-14
KR102863322B1 (ko) 2025-09-22
GB2575623A (en) 2020-01-22
WO2019234402A1 (en) 2019-12-12
KR20210019052A (ko) 2021-02-19

Similar Documents

Publication Publication Date Title
IL287907A (en) Cancer treatment methods
IL270720A (en) Combination of treatments for cancer treatment
EP3641770A4 (en) CANCER TREATMENT METHODS
ZA201706616B (en) Method for treating cancer
SG10201913409VA (en) Methods for solid tumor treatment
SG11201708861VA (en) Methods for treating cancer
IL268430A (en) Methods for treating cancer using hsp90 inhibitors
IL273395A (en) Combined therapies for cancer treatment
LT3377516T (lt) Kompozicija vėžiui gydyti
IL257691A (en) A method for treating cancer
IL259996A (en) Combinations for cancer treatment
IL256836B (en) Methods for treating cancer using apilimod
ZA201804968B (en) Formulations for treating bladder cancer
EP3892282A4 (en) COMBINATIONS FOR TREATING CANCER
IL255022A0 (en) Cancer treatment methods
EP3260119A4 (en) Combination method for treating cancer
IL255018A0 (en) Cancer treatment methods
SG11202010528XA (en) Combinations for treating cancer
GB2575623B (en) 3-hydroxybutyrate esters for treating cancer cachexia
SG10201508795XA (en) Method for treating cancer
IL255016A0 (en) Cancer treatment methods
EP3221284A4 (en) 13-cis-ramba retinamides that degrade mnks for treating cancer
SG11202011434SA (en) Methods for the treatment of bladder cancer
EP3674398A4 (en) ECHOVIRUS FOR TUMOR TREATMENT
GB2571849B (en) Treatments for cachexia